 |
|
Localization and Reoperation Results for Persistent and Recurrent Parathyroid Carcinoma
Electron Kebebew, MD;
Cumhur Arici, MD;
Quan-Yang Duh, MD;
Orlo H. Clark, MD
Arch Surg. 2001;136:878-885.
Hypothesis Reoperation is safe and benefits patients with persistent and recurrent parathyroid carcinoma.
Design Retrospective study. The mean follow-up time was 8.1 years (median, 7 years; range, 1-23 years).
Setting A university tertiary referral center.
Patients Eighteen patients treated for parathyroid carcinoma from 1966 to 1999.
Results The mean serum calcium level was 13.7 mg/dL (3.43 mmol/L), and the parathyroid hormone (PTH) level was 1.6 to 20 times the upper limit of normal. Fourteen of 18 patients had persistent or recurrent parathyroid carcinoma and underwent 54 reoperations (28 at our institution). Mean time to recurrence was 4.8 years (range, 1-20 years). Symptoms of hyperparathyroidism were relieved in 86% of patients who had reoperation (P<.05). Reoperation for parathyroid carcinoma (25 locoregional and 3 distant) significantly reduced and normalized the serum calcium and PTH levels in 75% and 62% of the cases, respectively (P<.001). The preoperative serum calcium level was a significant predictor of postreoperative normalization of the serum calcium level but not extent of initial resection, PTH level, time to recurrence, concordance of localization studies, or patient age and sex (P<.01). Surgical complications consisted of 5 unilateral and 1 bilateral permanent recurrent laryngeal nerve palsies (2 intentionally resected en bloc), 1 transient hypoparathyroidism, 1 wound seroma, and 1 tracheoesophageal fistula. The sensitivity rates of sestamibi scan (n = 14), magnetic resonance imaging (n = 15), computed tomographic scan (n = 6), ultrasound (n = 13), and selective venous catheterization with PTH measurement (n = 6) were 79%, 93%, 67%, 69%, and 83%, respectively.
Conclusions Recurrence is common in patients with parathyroid carcinoma. Patients with this disease should have frequent, lifelong follow-up to ensure early detection of recurrence. Although reoperation for persistent or recurrent parathyroid carcinoma provides significant symptomatic relief and normalizes serum calcium and PTH levels in most patients, it is associated with some morbidity. Localizing studies of parathyroid carcinoma are helpful but do not detect all tumor foci.
From the Department of Surgery, University of California, San Francisco, and Mount Zion Medical Center (Drs Kebebew and Clark), and Surgical Services, Veterans Affairs Medical Center (Dr Duh), San Francisco, Calif; and Department of General Surgery, Akdeniz University Antalya, Turkey (Dr Arici).
RELATED ARTICLE
Archives of Surgery Reader's Choice: Continuing Medical Education
Arch Surg. 2001;136(8):969-970.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Intra-operative Parathyroid Hormone Monitoring in Patients with Parathyroid Cancer
Solorzano et al.
Ann. Surg. Oncol. 2007;14:3216-3222.
ABSTRACT
| FULL TEXT
Cinacalcet Hydrochloride Reduces the Serum Calcium Concentration in Inoperable Parathyroid Carcinoma
Silverberg et al.
J. Clin. Endocrinol. Metab. 2007;92:3803-3808.
ABSTRACT
| FULL TEXT
Primary Hyperparathyroidism: Can Parathyroid Carcinoma Be Anticipated on Clinical and Biochemical Grounds? Report of Nine Cases and Review of the Literature
Robert et al.
Ann. Surg. Oncol. 2005;12:526-532.
ABSTRACT
| FULL TEXT
Relationship of AgNOR counts and nuclear DNA content to survival in patients with parathyroid carcinoma
Lumachi et al.
Endocr Relat Cancer 2004;11:563-569.
ABSTRACT
| FULL TEXT
Hormonal and Biochemical Normalization and Tumor Shrinkage Induced by Anti-Parathyroid Hormone Immunotherapy in a Patient with Metastatic Parathyroid Carcinoma
Betea et al.
J. Clin. Endocrinol. Metab. 2004;89:3413-3420.
ABSTRACT
| FULL TEXT
|
